Clinical trials: insulin glargine
- Drug or intervention insulin glargine
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Diabetes, Type I
Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes
To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
- Trial name
- NCT00308308
- Testing
- Technosphere Insulin, Active comparator
- Where
- 129 sites in United States, Argentina and 8 more
- Volunteers
- 589 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Healthy Participants
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS Glargine (G), United States (US)-Lantus®, and…
- Trial name
- NCT06627478
- Testing
- NKF-INS(G), US-Lantus®, EU-Lantus®
- Where
- South Africa
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Xentria, Inc.
Diabetes Mellitus, Type 2
Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients
The purpose of this phase IV clinical trial is to investigate the effect of Insulin glargine + metformin treatment vs. sulfonylurea + metformin treatment vs. DPP-4 + metformin treatment vs.
- Trial name
- NCT01206712
- Where
- Germany
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- ikfe-CRO GmbH
Healthy
A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of LY2963016 and US-approved Lantus®. The study involves four single injections; two doses of LY2963016 and two doses of US-approved Lantus®.
- Trial name
- NCT01688635
- Testing
- LY2963016, US Approved Lantus
- Where
- Singapore
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Diabetes Mellitus, Type 2
A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes
This study is investigating the safety and tolerability of the new medicine NNC0472-0147, its concentrations in the blood and its effect on blood sugar for the treatment of diabetes.
- Trial name
- NCT04262661
- Testing
- NNC0472-0147, insulin glargine
- Where
- 2 sites in Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy, Diabetes
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The purpose is to evaluate safety and tolerability of a range of single doses of subcutaneous insulin 338.
- Conditions
- Healthy, Diabetes, Diabetes Mellitus, Type 1
- Trial name
- NCT02220296
- Testing
- Insulin 338, insulin glargine
- Where
- Germany
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers
This is a randomised, double-blind, double-dummy, active-controlled, three-period crossover euglycemic clamp trial in healthy Chinese volunteers. Each subject will be randomly allocated to one of 6 treatment sequences.
- Trial name
- NCT05373186
- Testing
- Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Humalog® Mix25, Euglycemic clamp with Humalog® and Lantus®
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Adocia
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of NNC 0148-0000-0362 as tablets in healthy…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01597713
- Testing
- NNC 0148-0000-0362, insulin glargine
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of LY3209590 in Participants With Type 2 Diabetes
This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes.
- Trial name
- NCT03367377
- Testing
- LY3209590, Insulin Glargine
- Where
- 3 sites in United States, Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Subjects
To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy Subjects
The purpose of this study is to compare the pharmacodynamic profile of a single subcutaneous dose of SHR-3167 injection versus insulin glargine U100 in healthy subjects.
- Trial name
- NCT07588906
- Testing
- SHR-3167 injection；glargine insulin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects
This trial is conducted in Europe. The aim of this first human dose trial is to investigate the safety, tolerability, pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (exposure of the trial…
- Trial name
- NCT01809184
- Testing
- insulin 287, insulin glargine
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02479022
- Testing
- Insulin 320, insulin glargine
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants
The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in healthy Chinese participants. Blood samples will be taken to compare how the body handles the drugs and how they affect blood sugar…
- Trial name
- NCT03555305
- Testing
- Insulin Glargine, Lantus
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03170544
- Testing
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin.
- Trial name
- NCT01374178
- Testing
- LY2963016, Lantus
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Diabetic Complication
mHealth Titration and Management
The principal objective of this application is to improve glycemic control of diabetic patients treated with basal insulin through use of an innovative, FDA-cleared smartphone-based insulin titration application connected to…
- Trial name
- NCT03908762
- Testing
- iSage App with connected glucometer, Magnet
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Amalgam Rx, Inc.
Type 1 Diabetes Mellitus
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.
- Trial name
- NCT02666430
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 81 sites in United States, Canada and 6 more
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Diabetes Mellitus, Type 1, Healthy Volunteers
A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes
This study is investigating the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965), its concentrations in the blood and its effect on blood sugar for the treatment of diabetes.
- Trial name
- NCT03965013
- Testing
- NNC0268-0965, insulin glargine
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Safety of NNC 0123-0000-0338 in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body), and the pharmacodynamics (the effect of the investigated drug on…
- Trial name
- NCT01334034
- Testing
- NNC 0123-0000-0338, insulin glargine
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S